| Rheumatology | Lifetime | 39 | US 14 | 99.81 |
| Hepatology | Lifetime | 645 | US 231 | 90.18 |
| Medical Genetics | Lifetime | 887 | US 443 | 88.70 |
| Nephrology | Lifetime | 843 | US 385 | 86.34 |
| Rheumatology | 2021-2025 | 36 | US 10 | 99.37 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 469 | US 154 | 94.95 |
| Epidemiology | 2021-2025 | 750 | US 267 | 92.68 |
| Pathology and Forensic Medicine | 2021-2025 | 517 | US 165 | 73.16 |
| Systemic Lupus Erythematosus Research | Lifetime | 40 | US 11 | 99.74 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 33 | US 10 | 99.81 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | Lifetime | 121 | US 65 | 99.15 |
| Viral Infections and Immunology Research | Lifetime | 159 | US 82 | 98.76 |
| Sarcoidosis and Beryllium Toxicity Research | Lifetime | 55 | US 26 | 99.00 |
| Hepatitis C virus research | Lifetime | 276 | US 91 | 99.18 |
| Vasculitis and related conditions | Lifetime | 85 | US 30 | 98.87 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 182 | US 58 | 98.71 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 819 | US 382 | 98.01 |
| Spondyloarthritis Studies and Treatments | Lifetime | 250 | US 52 | 97.46 |
| Systemic Sclerosis and Related Diseases | Lifetime | 450 | US 140 | 96.80 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 590 | US 153 | 95.70 |
| Urticaria and Related Conditions | Lifetime | 648 | US 196 | 95.10 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 971 | US 359 | 94.57 |
| Eosinophilic Disorders and Syndromes | Lifetime | 891 | US 348 | 94.31 |
| Inflammatory Myopathies and Dermatomyositis | Lifetime | 504 | US 166 | 93.84 |
| Gout, Hyperuricemia, Uric Acid | Lifetime | 543 | US 163 | 91.33 |
| Otitis Media and Relapsing Polychondritis | Lifetime | 460 | US 110 | 88.90 |
| Case Reports on Hematomas | Lifetime | 708 | US 241 | 72.02 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 20 | US 5 | 99.34 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 67 | US 23 | 98.58 |
| Chronic Disease Management Strategies | 2021-2025 | 101 | US 23 | 96.25 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | 2021-2025 | 297 | US 82 | 94.72 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 396 | US 80 | 91.34 |
| Spondyloarthritis Studies and Treatments | 2021-2025 | 284 | US 45 | 91.89 |
| Sarcoidosis and Beryllium Toxicity Research | 2021-2025 | 221 | US 72 | 89.77 |
| Systemic Sclerosis and Related Diseases | 2021-2025 | 542 | US 107 | 87.05 |
| Vasculitis and related conditions | 2021-2025 | 415 | US 68 | 87.24 |
| Urticaria and Related Conditions | 2021-2025 | 538 | US 100 | 83.19 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 574 | US 121 | 79.87 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 988 | US 210 | 74.60 |
| Inflammatory Myopathies and Dermatomyositis | 2021-2025 | 707 | US 157 | 74.03 |
| Drug-Induced Ocular Toxicity | 2021-2025 | 111 | US 42 | 60.46 |
| Otitis Media and Relapsing Polychondritis | 2021-2025 | 904 | US 130 | 50.74 |
